JP2010514677A5 - - Google Patents

Download PDF

Info

Publication number
JP2010514677A5
JP2010514677A5 JP2009543119A JP2009543119A JP2010514677A5 JP 2010514677 A5 JP2010514677 A5 JP 2010514677A5 JP 2009543119 A JP2009543119 A JP 2009543119A JP 2009543119 A JP2009543119 A JP 2009543119A JP 2010514677 A5 JP2010514677 A5 JP 2010514677A5
Authority
JP
Japan
Prior art keywords
alkyl
hetero
propanamide
oxopyridin
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009543119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514677A (ja
JP5419706B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/087807 external-priority patent/WO2008079787A2/en
Publication of JP2010514677A publication Critical patent/JP2010514677A/ja
Publication of JP2010514677A5 publication Critical patent/JP2010514677A5/ja
Application granted granted Critical
Publication of JP5419706B2 publication Critical patent/JP5419706B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009543119A 2006-12-20 2007-12-17 グルコキナーゼアクチベーター Expired - Fee Related JP5419706B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87092906P 2006-12-20 2006-12-20
US60/870,929 2006-12-20
PCT/US2007/087807 WO2008079787A2 (en) 2006-12-20 2007-12-17 Glucokinase activators

Publications (3)

Publication Number Publication Date
JP2010514677A JP2010514677A (ja) 2010-05-06
JP2010514677A5 true JP2010514677A5 (enExample) 2011-02-10
JP5419706B2 JP5419706B2 (ja) 2014-02-19

Family

ID=39446103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543119A Expired - Fee Related JP5419706B2 (ja) 2006-12-20 2007-12-17 グルコキナーゼアクチベーター

Country Status (4)

Country Link
US (2) US8163779B2 (enExample)
EP (1) EP2091947A2 (enExample)
JP (1) JP5419706B2 (enExample)
WO (1) WO2008079787A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
CA2676173A1 (en) * 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
JP5513492B2 (ja) 2008-05-16 2014-06-04 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CA2729581A1 (en) * 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
JP2012515760A (ja) * 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド
WO2010103437A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
CN102884047B (zh) 2009-12-04 2015-11-25 日产化学工业株式会社 2-吡啶酮化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2014DN09554A (enExample) 2012-05-17 2015-07-17 Transtech Pharma Llc
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102160841B1 (ko) 2012-11-13 2020-09-28 닛산 가가쿠 가부시키가이샤 2-피리돈 화합물
CA2903433A1 (en) * 2013-03-04 2014-09-12 Vtv Therapeutics Llc Stable glucokinase activator compositions
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2015120777A1 (zh) * 2014-02-14 2015-08-20 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN105658641B (zh) * 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
ES2716417T3 (es) 2014-09-24 2019-06-12 Bayer Pharma AG Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica
WO2016046166A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
WO2016046156A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046158A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
JP6517925B2 (ja) * 2014-09-24 2019-05-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたオキソピリジン誘導体
EP3263133B8 (en) * 2015-02-27 2020-07-15 Kyushu University, National University Corporation Pyridinone compound and use thereof
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (de) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
WO2019063708A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
WO2019063704A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
DK3774796T3 (da) 2018-04-10 2022-07-18 Bayer Pharma AG Et substitueret oxopyridinderivat
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2020127508A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
EA202191764A1 (ru) 2018-12-21 2021-10-22 Байер Акциенгезельшафт Замещенные оксопиридиновые производные
AU2020383423B2 (en) 2019-11-11 2026-06-18 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US12479808B2 (en) 2020-06-08 2025-11-25 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
CN115811977A (zh) * 2020-06-09 2023-03-17 达纳-法伯癌症研究所股份有限公司 变构egfr抑制剂及其使用方法

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB921315A (en) 1958-03-31 1963-03-20 Wellcome Found The manufacture of 8-aminoalkylamino quinoline derivatives
US3956287A (en) 1973-11-07 1976-05-11 Richardson-Merrell Inc. 7-[(2-Oxo-1-pyridinyl)acylamino]cephalosporin derivatives
JPS62232555A (ja) 1986-04-02 1987-10-13 Unitika Ltd 酵素センサ
US4959212A (en) 1988-06-22 1990-09-25 Alexandra Stancesco Oxidizing-energizing composition and method for the treatment of diabetes
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
DE4211474A1 (de) * 1992-04-06 1993-10-07 Merck Patent Gmbh Imidazopyridine
US5541060A (en) 1992-04-22 1996-07-30 Arch Development Corporation Detection of glucokinase-linked early-onset non-insulin-dependent diabetes mellitus
DE69419639T2 (de) 1993-03-17 1999-12-16 Unitika Ltd., Amagasaki Verfahren zur Herstellung von Fructose-2,6-diphosphat und Reinigungsverfahren hierfür
JP3203108B2 (ja) 1993-08-26 2001-08-27 協和メデックス株式会社 グルコース−６−リン酸デヒドロゲナーゼの安定化方法
DE4341665A1 (de) 1993-12-07 1995-06-08 Basf Ag Bicyclen-Derivate, ihre Herstellung und Verwendung
US6486380B1 (en) 1993-12-17 2002-11-26 University Of North Dakota Medical Education Research Foundation Pancreatic β cell hexokinase transgene
US7041503B2 (en) 1995-05-02 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Modified myelin basic protein molecules
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
GB9618934D0 (en) 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
WO2002008288A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6642360B2 (en) 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
US20020032330A1 (en) 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
FR2758326B1 (fr) 1997-01-16 1999-02-12 Synthelabo Derives de pyridone, leur prepaparation et leur utilisation comme intermediaires de synthese
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ZA988460B (en) 1997-09-17 1999-03-19 Genentech Inc Polypeptides and nucleic acids encoding the same
US7378507B2 (en) 1997-09-18 2008-05-27 Genentech, Inc. PRO217 polypeptides
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US6894148B2 (en) 1997-11-12 2005-05-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030129691A1 (en) 1998-02-09 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040048332A1 (en) 1998-04-29 2004-03-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030073188A1 (en) 1998-07-07 2003-04-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2364417C (en) 1999-02-19 2013-11-05 Matthew John During Peroral gene therapy of diabetes and obesity
EP1263948A2 (en) 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
HK1046139B (zh) 1999-03-29 2004-12-10 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
RU2242469C2 (ru) 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6967019B2 (en) 1999-04-06 2005-11-22 The Regents Of The University Of California Production of pancreatic islet cells and delivery of insulin
US8193330B2 (en) 1999-04-06 2012-06-05 The Regents Of The University Of California Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains
US6774120B1 (en) 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
JP4447705B2 (ja) 1999-10-20 2010-04-07 独立行政法人科学技術振興機構 糖尿病発症モデル哺乳動物
US20040072739A1 (en) 1999-11-10 2004-04-15 Anderson Christen M. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
US6716582B2 (en) 2000-04-14 2004-04-06 E. I. Du Pont De Nemours And Company Cellular arrays for the identification of altered gene expression
AU2001295841A1 (en) 2000-04-25 2002-01-02 German Human Genome Project Human dna sequences
EP1282612B1 (en) 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
ATE304011T1 (de) * 2000-05-03 2005-09-15 Hoffmann La Roche Hydantoin-enthaltende glucokinase aktivatoren
US6489485B2 (en) 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
MXPA02010795A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Activadores de glucocinasa de fenilamida sustituida por para-amino.
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1404820A2 (en) 2000-05-19 2004-04-07 Millennium Pharmaceuticals, Inc. 50365, a hexokinase family member and uses therefor
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
JP2004500859A (ja) 2000-05-31 2004-01-15 プロメガ　コーポレイション キナーゼ及びホスファターゼ用の評価分析法
AU2001270215A1 (en) 2000-06-27 2002-01-08 Curagen Corporation Novel polynucleotides and polypeptides encoded thereby
WO2002006339A2 (en) 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
EP1303605A2 (en) 2000-07-19 2003-04-23 Eli Lilly And Company Nucleic acids, vectors, host cells, polypeptides, and uses thereof
CA2416229C (en) 2000-07-20 2007-09-18 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US20040044179A1 (en) 2000-07-25 2004-03-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030100709A1 (en) 2000-07-25 2003-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7371817B2 (en) 2000-07-25 2008-05-13 Genentech, Inc. PRO9783 polypeptides
US20030212255A1 (en) 2000-07-26 2003-11-13 Muralidhara Padigaru Novel proteins and nucleic acids encoding same
AU2001280471A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Novel secreted proteins and their uses
US6369232B1 (en) 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
JP2004512029A (ja) 2000-08-16 2004-04-22 カイロン　コーポレイション ヒト遺伝子および遺伝子発現産物
WO2002016578A2 (en) 2000-08-24 2002-02-28 Eli Lilly And Company Secreted proteins and methods of using same
WO2002016599A2 (en) 2000-08-25 2002-02-28 Curagen Corporation Proteins and nucleic acids encoding same
US6346416B1 (en) 2000-08-29 2002-02-12 Isis Pharmaceuticals, Inc. Antisense inhibition of HPK/GCK-like kinase expression
US6849728B1 (en) 2000-08-31 2005-02-01 Wake Forest University Health Sciences GLUT10: a glucose transporter in the type 2 diabetes linked region of chromosome 20Q12-13.1
US6689938B2 (en) 2000-09-13 2004-02-10 Oklajoma Medical Research Foundation Method for treatment of insulin resistance in obesity and diabetes
US20030187201A1 (en) 2000-09-15 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1325029A2 (en) 2000-09-28 2003-07-09 Eli Lilly And Company Secreted proteins and their uses
US20040142333A1 (en) 2000-10-19 2004-07-22 Deshun Lu Novel secreted proteins and their uses
WO2002057450A2 (en) 2000-11-29 2002-07-25 Curagen Corporation Proteins and nucleic acids encoding same
AU2002227239A1 (en) 2000-12-06 2002-06-18 Curagen Corporation Proteins and nucleic acids encoding same
EP1341774B1 (en) 2000-12-06 2006-02-01 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
WO2002064791A2 (en) 2000-12-08 2002-08-22 Curagen Corporation Proteins and nucleic acids encoding same
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
AU2002236440A1 (en) 2000-12-15 2002-06-24 Eli Lilly And Company Novel secreted proteins and their uses
WO2002059315A2 (en) 2000-12-19 2002-08-01 Curagen Corporation Human nucleic acids and polypeptides and methods of use thereof
JP2005508601A (ja) 2000-12-19 2005-04-07 キュラジェン コーポレイション ポリペプチドおよびそれをコードする核酸
ES2170720B1 (es) 2000-12-20 2003-12-16 Univ Barcelona Autonoma Utilizacion conjunta del gen de la insulina y del gen de la glucoquinasa en el desarrollo de aproximaciones terapeuticas para la diabetes mellitus.
WO2002050277A2 (en) 2000-12-21 2002-06-27 Curagen Corporation Protein and nucleic acids encoding same
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
US7247705B2 (en) 2000-12-28 2007-07-24 Takeda Pharmaceutical Company Limited Proteins having glucose transporter activity
WO2002055704A2 (en) 2001-01-09 2002-07-18 Curagen Corp Proteins, polynucleotides encoding them and methods of using the same
EP1358327A2 (en) 2001-01-11 2003-11-05 Curagen Corporation Proteins and nucleic acids encoding same
JP4146095B2 (ja) 2001-01-15 2008-09-03 ユニチカ株式会社 耐熱性グルコキナーゼ遺伝子、それを含有する組換えベクター、その組換えベクターを含有する形質転換体及びその形質転換体を用いた耐熱性グルコキナーゼの製造方法
WO2002057435A2 (en) 2001-01-18 2002-07-25 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
GB0101447D0 (en) 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
WO2002081517A2 (en) 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby
US20040081981A1 (en) 2001-01-31 2004-04-29 Toru Egashira Method of detecting risk factor for onset of diabetes
WO2002068649A2 (en) 2001-01-31 2002-09-06 Curagen Corporation Proteins and nucleic acids encoding same
US20040086875A1 (en) 2001-11-05 2004-05-06 Agee Michele L. Novel proteins and nucleic acids encoding same
US20040053245A1 (en) 2001-02-05 2004-03-18 Tang Y. Tom Novel nucleic acids and polypeptides
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2002072757A2 (en) 2001-03-08 2002-09-19 Curagen Corporation Novel proteins and nucleic acids encoding same
US20050089852A1 (en) 2001-03-14 2005-04-28 Lee Shao C. Method and compositions for evaluating risk of developing type 2 diabetes in people of chinese descent
JP4602577B2 (ja) 2001-03-15 2010-12-22 積水メディカル株式会社 前糖尿病状態のスクリーニング方法及びスクリーニング用試薬
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7186818B2 (en) 2001-04-26 2007-03-06 Immunex Corporation DNA encoding soluble variants of human OX2 receptors
WO2002093127A2 (en) 2001-05-11 2002-11-21 Adipogenix, Inc. Methods and reagents for identifying insulin response modulators and therapeutic uses therefor
WO2002092756A2 (en) 2001-05-15 2002-11-21 Rappaport Family Institute For Research In The Medical Sciences Insulin producing cells derived from human embryonic stem cells
EP2161578A1 (en) 2001-05-29 2010-03-10 Pride Proteomics A/S Proteins in diabetes proteome analysis
US7157558B2 (en) 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
AU2002312211A1 (en) 2001-06-01 2002-12-16 Clingenix, Inc. Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
JP2005501530A (ja) 2001-06-08 2005-01-20 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 体細胞株におけるヒトインスリンのグルコース−調節された産生のために有用な核酸構築物
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
JP4509570B2 (ja) 2001-07-03 2010-07-21 ジェネンテック， インコーポレイテッド ヒトｄｒ４抗体及びその使用法
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
EP1453541A1 (en) 2001-12-03 2004-09-08 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20030023042A1 (en) 2001-12-06 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
DE10162730A1 (de) 2001-12-20 2003-07-03 Degussa Allele des glk-Gens aus coryneformen Bakterien
KR101018318B1 (ko) * 2001-12-21 2011-03-04 노보 노르디스크 에이/에스 Ｇｋ 활성제로서의 아미드 유도체
EP1572149A2 (en) 2002-03-07 2005-09-14 The Forsyth Institute Immunogenicity of glucan binding protein
WO2003080585A1 (en) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
US20030232370A1 (en) 2002-04-22 2003-12-18 Trifiro Mark A. Glucose sensor and uses thereof
BR0309546A (pt) 2002-04-26 2005-02-15 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
US20040053948A1 (en) * 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
AU2003235307A1 (en) 2002-05-16 2003-12-02 Banyu Pharmaceutical Co., Ltd. Crystal of glucokinase protein, and method for drug design using the crystal
US20060228706A1 (en) 2002-06-04 2006-10-12 Metabolex, Inc. Methods of diagnosing and treating diabetes and insulin resistance
WO2003102163A2 (en) 2002-06-04 2003-12-11 Metabolex, Inc. Methods of diagnosing and treating diabetes and insulin resistance
WO2003102161A2 (en) 2002-06-04 2003-12-11 Metabolex, Inc. Methods of diagnosing & treating diabetes and insulin resistance
JP2006503265A (ja) 2002-06-05 2006-01-26 メタボレックス インコーポレーティッド 糖尿病およびインスリン抵抗性の診断および治療の方法
AU2003237483A1 (en) 2002-06-05 2003-12-22 Metabolex, Inc. Methods of diagnosing and treating diabetes and insulin resistance
JP2005529603A (ja) 2002-06-13 2005-10-06 メタボレックス インコーポレーティッド 糖尿病を予防、治療、および診断するための組成物および方法
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
KR100442832B1 (ko) 2002-07-10 2004-08-02 삼성전자주식회사 다중 중합효소 연쇄반응에 의한 ｍｏｄｙ２ 유전자의증폭을 위한 프라이머 세트
WO2004006838A2 (en) 2002-07-15 2004-01-22 Sugen, Inc. Novel kinases
US7087631B2 (en) 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US20040132679A1 (en) 2002-09-03 2004-07-08 Baylor College Of Medicine Induction of pancreatic islet formation
ES2293005T3 (es) 2002-10-03 2008-03-16 F. Hoffmann-La Roche Ag Indol-3-carboxamidas como activadores de la glucocinasa.
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
AU2003285069A1 (en) 2002-10-28 2004-05-25 Joslin Diabetes Center, Inc. Type 2 diabetes mellitus genes
US20040108226A1 (en) 2002-10-28 2004-06-10 Constantin Polychronakos Continuous glucose quantification device and method
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
DE10258885A1 (de) 2002-12-17 2004-07-15 Aventis Pharma Deutschland Gmbh Verfahren zur Generierung eines gentechnisch veränderten Organismus
WO2004063194A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2004069194A2 (en) 2003-02-03 2004-08-19 The Brigham And Women's Hospital, Inc. Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
BRPI0407283A (pt) 2003-02-13 2006-01-31 Banyu Pharma Co Ltd Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
US20040180845A1 (en) 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
US20040185548A1 (en) 2003-03-17 2004-09-23 Qun-Sheng Ji Hybrid receptors for efficient assay of modulators of receptor protein-tyrosine kinases
US20040198969A1 (en) 2003-04-01 2004-10-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JPWO2004096806A1 (ja) * 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
US7179613B2 (en) 2003-05-05 2007-02-20 Vanderbilt University Methods of screening for a candidate modulator of glucokinase
AU2004235872A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
JP2007503453A (ja) 2003-05-14 2007-02-22 ノボ　ノルディスク　アクティーゼルスカブ 肥満症を治療するための新規化合物
US20050008691A1 (en) 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
US20050043391A1 (en) 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
CA2549017A1 (en) 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
AU2004261663A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
WO2005014532A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
WO2005030032A2 (en) 2003-09-22 2005-04-07 The Regents Of The University Of Colorado Use of islet glucose-6-phosphatase related protein as a diagnostic tool and therapeutic target for autoimmune diabetes
GB0327760D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
MX2007001650A (es) * 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
WO2006035954A1 (en) * 2004-09-28 2006-04-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
EP2001875A2 (en) * 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
WO2007108968A2 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP5415942B2 (ja) * 2006-06-22 2014-02-12 プラナ バイオテクノロジー リミティッド 処置の方法およびその処置に有用な薬剤
CA2729581A1 (en) * 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls

Similar Documents

Publication Publication Date Title
JP2009531309A5 (enExample)
ES2344347T3 (es) Derivados de cianopiridina novedosos utiles en el tratamiento de cancer y otros trastornos.
AU2014373735B2 (en) Therapeutic inhibitory compounds
AU2002341921B8 (en) Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CA2718393C (en) Pyridylaminoacetic acid compound
JP5556924B2 (ja) 緑内障の治療又は予防のための医薬組成物
AU2020202167A1 (en) Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
JP2005526814A5 (enExample)
WO2005117867A2 (en) Monocyclic heterocycles as kinase inhibitors
RU2012126989A (ru) 2-амино-5,5-дифтор-5,6-дигидро-4н-оксазины в качестве ингибиторов васе 1 и(или) васе 2
JP2007508346A5 (enExample)
TW200529830A (en) A thiazole derivative
MXPA05009102A (es) Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos.
JP2011520915A5 (enExample)
CA2599974C (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
JP2011503230A5 (enExample)
JP2020512401A5 (enExample)
JP2019505595A5 (enExample)
TWI794844B (zh) 包含經由鏈接子連接之2或更多芳基或雜芳基的新穎羰基亞肼基二氰化物化合物及其用途
EP1608639A2 (en) Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
JP2008526840A5 (enExample)
JP2011057633A (ja) ピリジルアミノ酢酸化合物を含有する医薬
JP2007527899A5 (enExample)
JP2023551139A (ja) Ｂ型肝炎ウイルス感染症の処置および予防のためのビシクロ［１．１．１］ペンタン化合物
JP2014500252A5 (enExample)